FDA Approves NuPathe’s Migraine Skin Patch- PATH

Northern, WI 1/20/2013 (avauncer) – The Food and Drug Administration cleared the treatment known as Zecuity which is product of NuPathe Inc. (NASDAQ:PATH), a maker of neurological and psychiatric medicines. The Food and Drug Administration (FDA), in the U.S. green signaled the company to sell the first skin patch to treat migraines that involves sumatriptan, the most-prescribed migraine headache medication, through a mild electrical current. This was reported by Conshohocken, Pennsylvania-based NuPathe yesterday in a statement.

Armando Anido, NuPathe’s chief executive officer, also confirmed the product would be available in the fourth quarter of this year for public use. He said the company is now in talks with various peoples across the U.S. for partnerships in the enterprise.

The therapy was rejected in August 2011 by the FDA citing the safety issues associated with it, however the FDA was certain about the effectiveness of the therapy. The company has worked on its design since then and has improved it significantly.

Anido said that the decision came in the wake of some signals around skin reaction. He also briefed about how the therapy went through rigorous improvement so that the error can be adjusted and the reactions can be eliminated.

Migraine being a neurological disorder affects around 31 million adults in the U.S. Migarine patients suffers nausea and vomiting besides headache.

Anido declines to disclose the price of the therapy however he hints the price to be somewhere close to the $95 priced similar medication which is injected into the patient’s body.

NuPathe Inc. (NASDAQ:PATH) plunged by 1% to $3 at the close of trading in New York. However the shares have increased by 53% in the past 12 months.